Advancing age is a strong risk factor for adverse outcomes across multiple disease processes. However, septic surgical and trauma patients are unique in that they incur two or more inflammatory insults. The effects of advanced age on sepsis pathophysiology and outcomes remain unclear.
A dvancing age is a well-known risk factor for increased morbidity and mortality across a wide range of disease processes, including traumatic injury, sepsis and acute critical illness. [1] [2] [3] In addition to clinically obvious factors, such as increasing incidence and severity of comorbidities and frailty, the aging process has also been shown to have a significant effect on the innate immune system. The phenomenon of "inflammaging," which is a state of low-grade chronic systemic inflammation associated with physiologic aging, has been extensively described. 4, 5 Additionally, the innate immune response after shock states is known to differ between the young and the aged. Previous work has shown that advanced age in patients with hemorrhagic shock is associated with an aberrant leukocyte genomic response, abnormal myelopoiesis, and dysfunctional innate immunity. 1, 6 Similar findings are found in preclinical models of sepsis, but the mechanism, magnitude, and persistence of immune dysfunction after sepsis has yet to be fully elucidated. 7 We have shown previously that shock states after both severe injury and sepsis are associated with a similar phenotype of persistent inflammation, immunosuppression, and catabolism. [8] [9] [10] [11] [12] However, the effect of age on the innate immune response in critically ill patients after sepsis remains incompletely defined. Therefore, we sought to further characterize the role of advancing age on the innate immune response to sepsis and its association with adverse clinical outcomes. Prior to undertaking an exploratory analysis of an ongoing prospective cohort study of surgical intensive care unit (ICU) patients with sepsis, we hypothesized that advanced age would be associated with a biomarker immunophenotype consistent with an abnormal innate immune response, a delayed trajectory of immunologic recovery, and would be associated with poor clinical outcomes, including increased number and severity of organ dysfunction, increased intensive care resource utilization, and higher inpatient mortality. Additionally, given the continuing trend of decreasing inpatient mortality after sepsis, we hypothesized that in sepsis inpatient survivors, those with advanced age would have higher rates of discharge disposition to resource intensive facilities, known to be associated with dismal long-term outcomes.
MATERIALS AND METHODS

Study Design, Inclusion/Exclusion Criteria, and Enrollment
This prospective observational cohort study consecutively enrolled trauma and surgical ICU patients that were admitted with, or subsequently developed sepsis over a four and a half year period (2012-2016) at a quaternary academic medical and Level I trauma center (UF Health, Gainesville, FL). This study was approved by the institutional review board of the University of Florida and registered with clinicaltrials.gov (NCT02276417). Overall program study design and protocols for the Sepsis and Critical Illness Center research program have been published for further reference. 13 Additional methodologic details relevant to this analysis are also available in Supplemental Digital Content (see Supplemental Digital Content 1, http://links. lww.com/TA/B136). Sepsis screening, diagnosis, resuscitation, and management were performed with uniform evidence-based sepsis management protocols supplemented by computerized clinical decision support to ensure timely and standardized intensive care. 13 Inclusion criteria for this analysis were the same as for the overall Sepsis and Critical Illness Center cohort and included the following: (1) age, 18 years or older; (2) clinical diagnosis of severe sepsis, or septic shock as defined by 2001 consensus guidelines; 14 and (3) entrance into the ICU sepsis clinical management protocol. All study patients subsequently underwent final clinical adjudication in prospective fashion by the physician investigators at weekly program adjudication and retention meetings. At that time, those whose clinical picture did not subsequently support a diagnosis of sepsis were excluded from further participation in the study and not included in subsequent analyses. 13 Exclusion criteria consisted of any of the following: (1) refractory shock (death <24 hours from sepsis protocol initiation) or inability to achieve source control; (2) preadmission expected lifespan less than 3 months; (3) patient/proxy not committed to aggressive management; (4) severe CHF (NYHA Class IV); (5) Child-Pugh Class C liver disease or preliver transplant; (6) known HIV with CD4+ count <200 cells/mm 3 ; (7) patients receiving chronic corticosteroids or immunosuppressive agents, including organ transplant recipients; (8) pregnancy; (9) institutionalized patients; (10) inability to obtain informed consent within 96 hours of enrollment; (11) chemotherapy or radiotherapy within 30 days; (12) severe traumatic brain injury; and (13) spinal cord injury resulting in permanent sensory and/or motor deficits. These criteria were used to focus on a population likely to survive the initial insult of sepsis to study the subsequent effects on the innate immune response, and whose severe comorbidities or severe functional injuries (i.e., TBI/SCI) would not be the primary determinant of subsequent clinical outcomes.
Patient demographics, comorbidities, sepsis diagnosis, and severity adjudication and clinical outcomes were manually collected in prospective fashion. Additionally, raw clinical data from the electronic medical record, including information on patient laboratory results, vital signs, medications, and information related to hospital and SICU admission and discharge, were directly uploaded to an analytical database by the University of Florida Health Integrated Data Repository. 13 
Patient Cohort and Outcomes Classification
Age-based cohorts were designated a priori as "young" (<55 years) or "aged" (≥55 years) based on previous age-related outcomes data after severe trauma patients admitted to surgical ICUs. 1, 3 Subsequent sensitivity analysis confirmed this dichotomization as optimal for differentiation of clinical outcomes and biomarker profiles in this sepsis population (see Results). Primary clinical outcomes included hospital mortality, ICU length of stay (LOS), incidence and severity of multiple organ failure, clinical trajectory and discharge disposition. Clinical trajectory was defined as "early death," "rapid recovery," or "chronic critical illness" (CCI). Chronic critical illness was defined as an ICU LOS greater than or equal to 14 days with evidence of persistent organ dysfunction, determined using components of the Sequential Organ Failure Assessment score (see Supplemental Digital Content 1, http://links.lww.com/TA/B136). 13 Rapid recovery patients were those who did not meet criteria for CCI or early death (death <14 days after sepsis protocol onset). Discharge disposition was classified based on known association with long-term outcomes as either "good" (home, home with health care service, or rehabilitation facility), or "poor" (longterm acute care facility [LTAC]), skilled nursing facility [SNF] , another acute care hospital, hospice, or inpatient death).
Biomarker Analyses
For this prospective cohort study, a set of a priori immune biomarkers were proscribed prior to study onset based on the cohort study's underlying mechanistic hypotheses regarding persistent inflammation, immunosuppression, and catabolism after sepsis (see Supplemental Digital Content 1, http://links.lww. com/TA/B136). 13 Based on preliminary data, a focused set of peripheral biomarkers were selected from the overall sampling panel for this age-focused analysis, including (IL-6, IL-8, TNF-α, C-reactive protein), immunosuppression (absolute lymphocyte count [ALC], IL-10 and soluble programed death ligand 1 [sPDL-1]), and catabolism (insulin growth factor 1 [IGF1], insulin-like growth factor binding protein 3 [IGFBP3] , albumin) at 12 hours, 1 day, 4 days, 7 days, 14 days, and weekly thereafter while hospitalized. Biomarker analyses were performed using the MILLIPLEX Multiplex (Merck KGaA, Darmstadt, Germany) and Luminex MAGPIX (Luminex Corp., Austin, TX) systems. Additionally, urine was collected at these time points to determine 3-methylhistidine (3-MH/Cr) to creatinine ratios as a measure of protein catabolism. 3-MH/Cr analyses were performed by Heartland Assays (Metabolic Technologies Inc., Ames, IA).
Statistical Analysis
We present data as either frequency and percentage, or mean and standard deviation, or median and 25th/75th percentiles. We used Fisher's exact test and Kruskal-Wallis test for comparison of categorical and continuous variables, respectively. We compared measured biomarkers using nonparametric rank tests of medians to determine significant differences between groups at each time point. Biomarker trajectories were modeled via generalized estimating equations with Poisson variance assumption and log link to determine differences in the trajectory of means between groups over time. Six-month survival analysis was performed using the Kaplan-Meier method and Log-rank test. All significance tests were two-sided, with p value of 0.05 or less considered statistically significant. We applied a post hoc Benjamini and Hochberg procedure to the clinical outcome variables to control for false discovery rate (FDR) less than 5%. 15, 16 Briefly, the individual p values are placed in order, from smallest to largest. The smallest p value has a rank of i = 1, then next smallest has i = 2, etc. Each individual p value is compared to its Benjamini-Hochberg critical value, (i/m)Q (q-value) where i is the rank, m is the total number of tests, and Q is the FDR (i.e., 0.05). The largest p value that has p < q is significant, and all of the P values smaller than it are also significant, even the ones that are not less than their Benjamini-Hochberg critical value. We performed all statistical analyses with SAS (v.9.4, Cary, NC).
RESULTS
Cohort Demographics, Sepsis Diagnosis, and Severity
One hundred seventy-three ICU patients that were admitted with, or developed, severe sepsis/septic shock were consecutively enrolled over the study period. Overall and age-defined cohort characteristics are shown in SDC 2 (see Supplemental Digital Content 2, http://links.lww.com/TA/B136) and Table 1 . The overall study population represents a relatively older aged cohort of patients (mean age, 60.9 years), with a significant comorbidity burden (median Charlson comorbidity score, 4) and severe physiologic derangement at 24 hours after sepsis onset (median APACHE II score, 22) (see Supplemental Digital Content 2, http://links.lww.com/TA/B136). The most common locations from which patients were admitted to the ICU included the operating room (42%), direct ICU interfacility transfer (22%), and the emergency department (21%). The majority of patients were admitted to the hospital with an acute, infection-related diagnosis, had intra-abdominal infection as the septic source, and approximately 65% underwent a source control procedure (Table 1 ; see Supplemental Digital Content 2, http://links.lww. com/TA/B136). Preliminary sensitivity analyses revealed that age dichotomization at 55 years maximized differentiation in clinical outcomes and a priori selected biomarker profiles between "young" and "aged" cohorts for subsequent analyses.
Young and aged cohorts were similar with regard to baseline characteristics with the exception of the aged cohort carrying a higher comorbidity burden ( Table 1 ). The aged cohort exhibited a clinically, but not statistically, significant higher incidence of vasopressor-dependent septic shock (51% vs. 34%, p = 0.0598, Table 1 ). At 24 hours after sepsis protocol initiation, the aged cohort also had a higher degree of physiologic derangement as measured by APACHE II score (Table 1) . 
Organ Dysfunction and Clinical Outcomes
Overall in-hospital mortality for the study population of critically ill sepsis patients was 12% (see Supplemental Digital Content 3, http://links.lww.com/TA/B136). While having similar ICU and hospital length of stay, the aged cohort had significantly higher incidence and severity of multiple organ dysfunction (Table 2) . Inpatient mortality was significantly higher in the aged (16%) as compared with the young (2%) cohort ( Table 2) . As compared with the young cohort, the aged cohort had a significantly higher percentage of "poor" discharge dispositions (LTAC, SNF, another hospital, hospice) known to be associated with poor long-term outcomes, as opposed to discharge to home or a rehabilitation facility ( Table 2 ). The incidence of 6-month mortality in the aged was over three times greater than that of the young cohort (31% vs. 9%, p = 0.0027; Fig. 1) , and double the initial in-hospital mortality rate (inpatient, 31%; vs. 6 months, 16%).
Inflammation, Immunosuppression and Catabolism Biomarkers
Select biomarker profiles of inflammation, immunosuppression, and catabolism are shown in Figure 2 . As sampling was limited to alive inpatients, missing data points increased over time due to discharges, LTAC/SNF transfers and deaths, and are listed along with full biomarker data in SDC 4 (see Supplemental Digital Content 4, http://links.lww.com/TA/B136). In both young and aged cohorts, levels of IL-6, IL-8, and TNF-α were significantly and persistently elevated above the normal range of healthy controls up to 28 days after sepsis onset, consistent with large and sustained innate inflammatory response to infection (Fig. 2) . Both young and aged cohorts exhibited a similar, robust, and sustained acute phase response after sepsis, as measured by C-reactive protein levels (Fig. 2) . Time-dependent modeling revealed modest, but statistically significant differences between young and aged cohort inflammatory biomarker trajectories over time (Fig. 2) . IL-6 levels were similar between groups in both early response to sepsis and overall 28-day trajectory ( Fig. 2) . IL-8, IL-10, and TNF-α showed modestly increased elevations early after sepsis, with slightly slower trend toward normalization over time ( Fig. 2; see Supplemental Digital Content 4, http://links.lww.com/TA/B136). There were no significant differences between young and aged cohorts in the magnitude or trajectory of circulating recruitment chemokines, including GM-CSF, G-CSF, MCP1, MIP-1 , and SDF1 (SDC 4). Interestingly, IP-10, a known biomarker associated with chronic inflammatory conditions, was stably elevated from baseline to 28 days in the aged cohort, and may be suggestive of preexisting and chronic low-level inflammation (see Supplemental Digital Content 4, http://links.lww.com/TA/B136).
Biomarker trajectories associated with immune suppression (sPDL-1, ALC) were consistent with a persistent state of immunosuppression out to 28 days after sepsis, in both young and aged cohorts (Fig. 3A) . However, sPDL-1 levels remained persistently elevated in the aged cohort out to 28 days after sepsis, whereas the young cohort established a trajectory toward normalization. Additionally, cellular markers of immunosuppression were different between the young and aged cohorts. While both cohorts exhibited significantly decreased ALCs after sepsis, young subjects returned to normal levels by day 14, whereas aged individuals had persistent lymphopenia out to 28 days after sepsis onset. Also, the aged cohort had a significantly higher neutrophil to lymphocyte ratio (a marker of systemic inflammation and adaptive immune suppression) between 1 week and 2 weeks after sepsis (Fig. 3A) .
Biomarkers of protein catabolism revealed a state of increased protein catabolism after sepsis in all patients. However, the aged cohort exhibited evidence of a state of prolonged, persistent catabolism as compared with the young cohort. While the urine 3-MH/Cr ratio normalized in the young cohort by day 14, it remained persistently elevated in the aged cohort (Fig. 3B) . Additionally, the insulin growth factor/growth hormone axis (as measured by IFG1/IGFBP3) remained persistently suppressed out to 28 days in the aged as compared with the young cohort (Fig. 3B) . While prealbumin levels increased over time in both cohorts, albumin levels were higher in the young cohort at 21 days after sepsis onset than in the aged (see Supplemental Digital Content 4, http://links.lww.com/TA/B136). 
DISCUSSION
Based on ongoing improvements in critical care organ support and implementation of evidence-based clinical protocols, inpatient mortality after sepsis continues to decline. 2, 17, 18 While this may at first appear to be a story of success, the long-term mortality and function of sepsis survivors remains unclear. As survivorship increases, CCI (>14 days ICU LOS with ongoing organ dysfunction) is now common (19% incidence) after severe trauma and is the predominant trajectory (49%) of surgical ICU patients with sepsis. 3, 11 It is therefore crucial to understand the risk factors, underlying mechanisms, and long-term outcomes associated with the development of CCI after these systemic, proinflammatory insults.
Advanced age is a known risk factor across a broad range of medical conditions. We have recently shown that advancing age is an independent predictor of inpatient mortality and poor discharge disposition among those that initially survive both severe trauma and surgical sepsis. 3, 11 In this current study, we found that surgical ICU patients older than 55 years of age appear to have more profound shock, greater severity of organ dysfunction, and higher incidence of adverse clinical outcomes after sepsis. Inpatient mortality in the aged was nearly eightfold higher than those younger than 55 years. While age-associated inpatient mortality after sepsis has been thoroughly reported, the long-term mortality of aged sepsis survivors is incompletely understood. Two thirds of patients older than 55 years had an inpatient disposition (LTAC, SNF, inpatient facility, hospice) known to be associated with high 1-year to 2-year mortality rates.
19,20 Additionally, we were able to show through prospective follow-up that while inpatient mortality after sepsis in the aged is 19%, mortality jumps to a striking 31% at 6 months. The reasons behind these dismal outcomes in the aged after sepsis are surely multifactorial, including a higher burden of chronic comorbidities. Additionally, there is some truth in the adage that "age is merely a number." Chronologic age as a predictor is very likely a reflection of its high correlation with underlying physiologic frailty which is probably the true factor driving these poor outcomes. [20] [21] [22] Unfortunately, we did not measure specific frailty metrics in this study population. However, we have incorporated baseline and serial follow-up frailty measurements into an ongoing prospective cohort study (NCT02276417).
While the adverse outcomes seen in advancing age after sepsis are multifactorial, we have shown evidence here that there are clear age-dependent differences in the physiologic and innate immunologic responses after sepsis. Both young and aged patients mounted a robust proinflammatory response early after sepsis, with prolonged elevation of circulating inflammatory cytokines above the level of healthy, normal controls for up to 28 days after sepsis onset (Fig. 2) . This is consistent with other recent findings documenting a state of prolonged, dysfunctional inflammation after sepsis. 10, 23, 24 While the differences in the initial inflammatory response as measured by circulating proinflammatory biomarkers were modest at best, there is clear differentiation between young and aged individuals regarding resolution of biomarker profiles consistent with post-sepsis (Fig. 3) . 25, 26 There is now an increasing literature base noting striking similarities between cancer and post-sepsis immunosuppression through mechanisms, such as the programed death ligand signaling pathway. 11, 27 Additionally, secondary infections have been shown to be predictors of the development of CCI and increased mortality in surgical ICU patients. 11, 28, 29 As the development of CCI after sepsis is known to be associated with poor hospital discharge disposition and high 6-month mortality, breaking the cycle of persistent immunosuppression after sepsis is an attractive target for interventional trials of immune checkpoint inhibitors. 30, 31 Accordingly, a multicenter phase III clinical trial investigating the effects of blockade of the PD-1 pathway after sepsis has recently begun enrollment (NCT02960854).
Sarcopenia and muscle wasting is another common clinical manifestation of persistent critical illness, is postulated to be associated with both systemic and local inflammation, and likely contributes to poor functional outcomes as a barrier to successful physical rehabilitation. 32, 33 Recently, we have shown evidence that a biomarker profile of persistent protein catabolism can be seen in surgical ICU patients that go on to develop CCI. 12 Here we have shown further evidence that a persistent state of protein catabolism after sepsis, and that this fails to resolve in the aged (Fig. 3B ). This suggests that dysfunctional inflammation after sepsis may be closely linked to CCI-associated sarcopenia and supports the hypothesis that a multimodality approach to interventional therapies will be necessary.
There are several limitations to this study which warrant discussion. As a single-center study at a large referral quaternary medical center, these findings will need replication among a broader population of critically ill septic patients. Additionally, while we have shown biomarker patterns and trajectories consistent with the persistent inflammation, immunosuppression, and catabolism syndrome with notable differences in magnitude and permanence between the young and aged, further characterization of immunologic functional deficits are required. We chose to identify the trend of persistent inflammation, immunosuppression, and catabolism syndrome phenotype across multiple mechanistically overlapping biomarkers to avoid the limitations of the choice of a single, possibly flawed selection of an individual biomarker. With this choice, we accepted the increased possibility of a single false-positive result. Thus individual biomarker findings at any given time point, or their use in prediction of outcomes, must be interpreted with caution. We currently have ongoing studies that will investigate this with functional immune effector cell assays to demonstrate functional immunosuppression, and radiographic and biopsy analyses to confirm sarcopenia and its association with long-term physical function. We also acknowledge that our sepsis severity and inclusion criteria are based on 2001 consensus definitions, as this study was designed prior to publication of consensus Sepsis-3 criteria. Compared with Sepsis-3 criteria, this study likely enrolled a subset of patients of lower organ dysfunction severity at time of sepsis onset. However, we would argue that any infection in the ICU setting is of significant clinical significance and likely to detrimentally contribute to the already perturbed innate immune response. Regardless, we do not believe the choice of consensus criteria for classification purposes affects the outcomes of this analysis of clinically significant infection in the surgical ICU.
In summary, we have shown that there are significant differences between young and aged patients in the physiologic and innate immune response of septic critically ill surgical patients. Aged, critically ill patients have more profound shock, greater organ dysfunction, and incidence of adverse clinical outcomes after sepsis. The 6-month mortality of aged septic patients is strikingly dismal, and three times higher than the rate of inpatient mortality. Based on circulating biomarker patterns, aged septic patients show evidence of an immunophenotype of persistent inflammation, immunosuppression, and catabolism. Scott, thanks for letting us know a few days ago that you were safe. Your friends in Seattle were happy to hear this. And thank you for sending the manuscript last month to give me time to read and digest all the data. After all, I'm almost aged and do things much slower than years past. And since you can't see me, I'm going to take my glasses off now to read my comments.
For a bit of background, Brakenridge and colleagues from the University of Florida have taken the lead in helping us understand what we're all seeing more in our surgical and intensive care units. They've given it a name: persistent inflammation immune suppression and catabolism syndrome.
This work is an example of translational research that takes advantage of our expertise; and I think this is important as observant clinicians, collaborating with very talented and interested bench researchers, to understand and to solve important clinical problems.
The first step is to define the problem. The second is to begin to decipher the complex biology behind it: in this case, what is the role of aging in the response to injury and to surgical infections that contributes to poor outcomes.
There are a lot of data in this work and, as Scott knows, I'm mostly interested in those last few slides. I have a few questions but I have one suggestion before getting to those.
I wonder if you could go back and look at your data without any preconceived notions of age and try to understand the outliers. As you know, this is one of my interests. Specifically, what are the mediator and metabolic profiles in your patients who were expected to do well but didn't? Conversely, what about those patients who didn't do well or who did well but were expected not to? Can you glean any information from their mediator profiles that might help you define hypotheses in the future?
I have a many more questions, but I will ask only two. First, what impact might the use of vasopressors and, conversely, beta antagonists, have on your measures of inflammation, immune suppression and catabolism? Could these agents, at least in part, explain your biomarker differences in the groups?
The second question refers to the 3-methylhistidine creatinine ratio, which is of particular interest to me. It remained elevated in the older patients. Assuming this observation is reproducible and that it is meaningful as an indicator of catabolism and protein synthesis, what would you propose we do to restore this to normal and perhaps improve the long-term outcomes of your patients?
Dr. Michael Yaffe (Boston, Massachusetts): Scott, really nice piece of work. I'm curious about two things.
One is if you segregate the older patients into those that had high IL10 and IL8 from those that had lower levels of IL10 and IL8, is it those patients with the higher levels that were the ones that you see at late times with increased PDL1 at 21 and 28 days and decreased IGF signaling?
And the second question is, the relationship between the older patients and the number of comorbidities, your data showed that about a third of your older patients had three or more comorbidities. Is it this particular subset that are the ones that go on to show this more severe immunosuppression?
Dr. Demetrios Demetriades (Los Angeles, California): You found that elderly patients had significantly abnormal immune system and biomarkers. My question is, are these abnormal biomarkers the result of the age or the more severe disease burden because they are much sicker than the younger patients?
Dr. Rosemary A. Kozar (Baltimore, Maryland): Two quick questions for you. The first, are the aged more hyper-inflammatory at baseline? And if so, were their first set of pro-inflammatory biomarkers significantly elevated? Is that a function of age or just a function of their response?
My second question is, where would you target a novel therapeutic? It appears as though the aged and the young respond similarly, it just takes the aged longer for the recovery period. Thank you.
Dr. Scott C. Brakenridge (Gainesville, Florida): Thank you very much. And my thanks to Dr. O'Keefe. His insights are wise, as always. And I have some answers for his questions, I hope.
As far as how to tease apart the mediator profiles and help give us insight into who is going to do well, who is not going to do well, who is going to progress on to things like progressive and persistent organ dysfunction and chronic critical illness, we're actually teasing apart those things now, trying to build prediction models based on inflammatory and immunosuppressive mediators, to come up with prediction models that will help us get a better look into the inside of what is going on at a mechanistic level.
Regarding the next question, I think that's really a chicken-before-the-egg type question. I really don't have a great answer about is it the vasopressors and/or is it the shock that's causing these immune-modulating effects.
It's a tough question to answer. I think we do know that vasopressors do have a mixed bag of effects on the innate inflammation.
But whether it is the insult or the inherent host response or the vasopressors, themselves that are causing these inflammatory changes between groups and leading to things like multiple organ failure and chronic critical illness, I think it's going to be hard to tease apart because they're all very colinear and track together. We have to keep that in mind, though.
Regarding your second question about how we're going to tackle these problems, especially the persistent catabolism, I think there is not going to be any one "magic bullet."
I think with regards to prevention of protein muscle loss and the functional disability that we see in these patients that are becoming ICU survivors, there is no "magic bullet."
It's going to be a multi-modality therapy. It's going to be early mobility, exercise, a combination of things perhaps like anabolic agents and aspects of nutritional supplementation.
And, most importantly, or one of the key aspects in my opinion at least, is the maintenance of immune competency, so that there aren't recurring insults like recurrent infections to keep setting these patients back, a second, third, and fourth hit.
Regarding the question for Boston, I'm sorry, I could not catch the name, regarding the early high IL10 and IL8 levels and the relationship to PDL1, again, these temporal relationships between the early response and the delayed immunosuppression is actually something we are actively working on, a great question. And I hope to get back to you on that in the not-too-distant future.
And another question about older patients and comorbidities, how that plays an effect in immunosuppression, I think Dr. Kozar and Dr. Demetriades also commented about that.
Yes, I think it's a combination of both age and comorbidity that are predisposing both to susceptibility and dysfunction in the innate immune response.
Dr. Demetriades' question about the age, is it the age or is it the comorbidity? Again, and I think importantly what people like Bellal Joseph has showed us is that if age is really just a number. Rather it's really the underlying physiologic frailty that is going to be the key here.
Unfortunately it's difficult to tease that apart, especially whether or not there is pre-existing inflammation prior to enrolling these patients. But that's a question we definitely have to pursue.
And for Dr. Kozar regarding the aged and are they hyperinflammatory at baseline, we're seeing that there are indeed agedependent differences in the innate immune response early in after sepsis. We've shown this before. Before the insult are they hyper-inflammatory?
You know data supporting the concept of "inflammaging" and aged dysfunctional immunity would suggest yes. I can't prove this in this data population because we don't sample them until after they're sick but a great thought and warrants further investigation.
And, finally, for Dr. Kozar, when will we target these novel therapeutics? I think we -this is just my personal opinion in the setting of a lot of great minds that are sitting in that room -but I think there has been a lot of futile efforts in trying to think that we can modulate the early explosion of the immune response.
Really what I think it's going to end up being is two factors: restoring immune competency and preventing people from becoming completely debilitated from protein catabolism and long-term muscle loss.
I hope I answered all your questions. Thank you so much to the association, Dr. Spain, and everybody else for giving me a chance to present from a distance.
